Login
$BBOT
$2.04 -$0.10 (4.67%) Live

$BBOT SEC Filings

Filed On Filing
13 Nov 2026 144
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients

05 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

23 Oct 2026 Form 4: Cobo Marc, Principal Accounting Officer

Gave up 203 shares to cover exercise price or tax ($544)

05 Oct 2026 Form 4: Cobo Marc, Principal Accounting Officer

Gave up 126 shares to cover exercise price or tax ($496)

05 Oct 2026 Form 4: Elmelech Idan, COO & Principal Financial Ofcr

Gave up 343 shares to cover exercise price or tax ($1.35K)

05 Oct 2026 Form 4: Beltran Pedro, Director

Gave up 1,047 shares to cover exercise price or tax ($4.13K)

05 Oct 2026 Form 4: Ben Yong, Chief Med & Dev Officer

Gave up 1,047 shares to cover exercise price or tax ($4.13K)

14 Sep 2026 Form 4: Cobo Marc, Principal Accounting Officer

Received 9,038 shares as a grant or award · Gave up 203 shares to cover exercise price or tax ($1.12K) · Granted 43,700 Stock Option (Right to Buy)

10 Sep 2026 EFFECT
08 Sep 2026 EFFECT
08 Sep 2026 8-K: Other Events

Corporate Update September 2026 BBOT Next-Generation RAS-Pathway Therapeutics

01 Sep 2026 S-3
01 Sep 2026 POS AM
12 Aug 2026 424B3
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Continued to advance monotherapy and combination cohorts for all clinical programs

06 Jul 2026 Form 4: Cobo Marc, Principal Accounting Officer

Gave up 125 shares to cover exercise price or tax ($975)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support